ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 36966334

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment.

Ruan R and 16 others. Mol Cancer, 2023. Cited by 111 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. Papers, record 36966334. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966334

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment.
PubMed
Journal
Mol Cancer
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
111
iCite
Relative citation ratio, by iCite
9.68
iCite
Revised in PubMed
2023-04-13
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ruan RRuiwen
2Li LLi
3Li XXuan
4Huang CChunye
5Zhang ZZhanmin
6Zhong HHongguang
7Zeng SShaocheng
8Shi QQianqian
9Xia YYang
10Zeng QQinru

1 to 10 of 17Source PubMed

See all 17 authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immune Checkpoint InhibitorsMajor topic
NeoplasmsMajor topic
Humans
Tumor Microenvironment
Receptors, Fibroblast Growth Factor
Fibroblast Growth Factors

Source PubMed

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
20192ACB20028Natural Science Foundation of Jiangxi ProvincePubMed
20202BCD42011Government of Jiangxi ProvincePubMed
20194009Government of Jiangxi ProvincePubMed
20202BABL216050Jiangxi Provincial Department of Science and TechnologyPubMed
GJJ190116Foundation of Jiangxi Educational CommissionPubMed
82260491National Natural Science Foundation of ChinaPubMed
20204BCJ23016Youth Science Foundation of Jiangxi ProvincePubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References196

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123,151,605Immunogenic cell death and DAMPs in cancer therapy.Nat Rev Cancer2012https://conductscience.org/library/papers/23151605PubMed
236,190,545FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures.Clin Cancer Res2022https://conductscience.org/library/papers/36190545PubMed
329,508,855Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/29508855PubMed
410,341,222Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function.J Cell Sci1999https://conductscience.org/library/papers/10341222PubMed
511,031,111Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors.Genomics2000https://conductscience.org/library/papers/11031111PubMed
629,443,960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018https://conductscience.org/library/papers/29443960PubMed
733,262,763A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.Front Immunol2020https://conductscience.org/library/papers/33262763PubMed
830,811,474Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.PLoS One2019https://conductscience.org/library/papers/30811474PubMed
928,187,290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
1026,903,404Regulation of FGF signaling: Recent insights from studying positive and negative modulators.Semin Cell Dev Biol2016https://conductscience.org/library/papers/26903404PubMed

1 to 10 of 196

See all 196 references

Cited by87

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 111 citations.

PMIDTitleJournalYearIn PapersSource
42,977,970FGFBPs in health and tumors: emerging prognostic biomarkers and therapeutic implications.Biomark Res2026https://conductscience.org/library/papers/42977970PubMed
42,824,816FGFR signaling and apoptotic regulation in cancer: links to immune evasion, therapeutic resistance, and treatment re-engagement.Front Immunol2026https://conductscience.org/library/papers/42824816PubMed
42,794,905Prognostic Value of EEF1A1 and Its Correlation with Immune Regulation in Kidney Renal Clear Cell Carcinoma.Cancers (Basel)2026https://conductscience.org/library/papers/42794905PubMed
42,729,787Advances in understanding the tumor microenvironment of neuroendocrine prostate cancer.Front Oncol2026https://conductscience.org/library/papers/42729787PubMed
42,713,707Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple-negative breast cancer.J Pathol2026https://conductscience.org/library/papers/42713707PubMed
42,711,318Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42711318PubMed
42,687,480Strategic driving of the cancer-immunity cycle in HCC: roles of immune, molecular-targeted, and locoregional therapies.J Liver Cancer2026https://conductscience.org/library/papers/42687480PubMed
42,591,661FGFR1 copy number gain is independently associated with shorter progression-free survival in advanced lung squamous cell carcinoma treated with first-line immune checkpoint inhibitor-based therapy.Front Immunol2026https://conductscience.org/library/papers/42591661PubMed
42,541,492Cancer-Associated Fibroblast-Derived FGF7 Promotes Immune Escape in Oral Squamous Cell Carcinoma via JAK/STAT3-Mediated PD-L1 Expression.Mol Carcinog2026https://conductscience.org/library/papers/42541492PubMed
42,394,340FGFR Inhibitor AZD4547 Disrupts Inflammatory CAF Crosstalk With Cancer Cells and Macrophages and Attenuates Metastasis in Pancreatic Cancer.FASEB J2026https://conductscience.org/library/papers/42394340PubMed

1 to 10 of 87

See all 87 cited by

Genes79

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT310,000PubTator's text mininghttps://conductscience.org/library/genes/10000NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
B2M567PubTator's text mininghttps://conductscience.org/library/genes/567NCBI Gene
BST2684PubTator's text mininghttps://conductscience.org/library/genes/684NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CDH51,003PubTator's text mininghttps://conductscience.org/library/genes/1003NCBI Gene
CIITA4,261PubTator's text mininghttps://conductscience.org/library/genes/4261NCBI Gene
CMA11,215PubTator's text mininghttps://conductscience.org/library/genes/1215NCBI Gene

1 to 10 of 79

See all 79 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36966334

GET https://conductscience.org/api/papers/v1/36966334/references?page=2

API referenceFor AI assistants